Product
Reparixin
Aliases
REP, Reparixin 600mg, Reparixin continuous infusion, reparixin intermittent infusion (1 other aliases)
9 clinical trials
12 indications
Indication
Ischemia/Reperfusion InjuryIndication
Kidney DiseasesIndication
PneumoniaIndication
Acute Respiratory Distress SyndromeIndication
AdultIndication
FatigueIndication
Severe COVID-19Indication
Breast CancerIndication
Pancreatectomy for Chronic PancreatitisIndication
ViralClinical trial
Randomized, Double-blind, Placebo-controlled, Parallel-group Pilot Study to Assess Efficacy, Safety and Pharmacokinetics of 2 Schedules of Reparixin in the Prevention of Delayed Graft Function After Kidney Transplant in High Risk PatientsStatus: Completed, Estimated PCD: 2008-05-01
Clinical trial
Study on the Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients With COVID-19 PneumoniaStatus: Terminated, Estimated PCD: 2020-11-27
Clinical trial
A Phase 3, Multicenter, Randomized, Double-blind, Parallel Assignment Study to Assess the Efficacy and Safety of Reparixin in Pancreatic Islet TransplantationStatus: Completed, Estimated PCD: 2016-12-01
Clinical trial
Phase 2, Randomized, Double-blinded, Placebo-controlled, Multicenter Study to Assess Efficacy and Safety of Reparixin as add-on Therapy to SoC in Acute Respiratory Distress Syndrome (RESPIRATIO)Status: Recruiting, Estimated PCD: 2024-05-01
Clinical trial
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 2 Study to Assess Efficacy and Safety of Reparixin in Cancer Related Fatigue in Pts With Advanced / Metastatic Breast Cancer Undergoing Taxane-based Chemotherapy.Status: Withdrawn, Estimated PCD: 2023-06-01
Clinical trial
Reparixin 1200 mg TID as add-on to SoC to Limit Disease Progression in Hospitalised Patients With COVID-19 and Other Community-Acquired Pneumonia. A Multicentre, Randomised, Double-blinded, Placebo-controlled, Phase III Trial (REPAVID-22)Status: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
A Randomized, Double-blind, Placebo-controlled Phase 2 Study of Paclitaxel in Combination With Reparixin Compared to Paclitaxel Alone as Front-line Therapy for Metastatic Triple- Negative Breast Cancer (FRIDA)Status: Completed, Estimated PCD: 2019-02-20
Clinical trial
A Phase 2/3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Assignment Study to Assess the Efficacy and Safety of Reparixin in Pancreatic Islet Auto-transplantationStatus: Completed, Estimated PCD: 2018-01-01
Clinical trial
A Phase 3, Double-blind, Randomized, Placebo-controlled, Multicenter Study on the Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients With Severe COVID-19 PneumoniaStatus: Completed, Estimated PCD: 2021-09-30